Gabay Michael
University of Illinois at Chicago, IL, USA.
Hosp Pharm. 2017 Dec;52(11):740-741. doi: 10.1177/0018578717739633. Epub 2017 Nov 9.
The Centers for Medicare and Medicaid Services (CMS) initially created direct and indirect remuneration (DIR) fees with the enactment of Medicare Part D in order to track rebates and other price adjustments made to pharmacy benefit managers (PBMs). PBMs have expanded the use of these fees to "claw back" money from pharmacies on already dispensed medications. Community and specialty pharmacies claim these fees are not transparent, hurt patients and taxpayers, and negatively impact their fiscal bottom line, while PBMs assert that these fees actually reduce premiums for patients. Congress has stepped into the dispute by introducing legislation that would halt retroactive DIR fees.
医疗保险和医疗补助服务中心(CMS)最初在《医疗保险处方药福利计划》(Medicare Part D)颁布时设立了直接和间接报酬(DIR)费用,以追踪向药品福利管理机构(PBMs)提供的回扣和其他价格调整。PBMs扩大了这些费用的用途,以便从药房收回已配药的款项。社区药房和专科药房称这些费用不透明,损害患者和纳税人利益,并对其财务底线产生负面影响,而PBMs则坚称这些费用实际上降低了患者的保费。国会已介入这场争端,提出了一项将停止追溯DIR费用的立法。